$VRNA
Verona Pharma PLC Stock $vrna

$vrna Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-K Financial Statement

#000165731223000006 Filed on March 07, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$0.00	$458.0K	$458.0K
YoY Change			-98.86%
Cost Of Revenue		$346.0K	$346.0K
YoY Change
Gross Profit		$112.0K	$112.0K
YoY Change			-99.72%
Gross Profit Margin		24.45%	24.45%
Selling, General & Admin	$9.590M	$8.323M	$26.58M
YoY Change	28.9%	44.57%	-21.61%
% of Gross Profit		7431.25%	23731.25%
Research & Development	$12.61M	$6.838M	$49.28M
YoY Change	-28.45%	-69.89%	-37.94%
% of Gross Profit		6105.36%	44002.68%
Depreciation & Amortization	$157.0K	$151.0K	$636.0K
YoY Change	-3.68%	-6.79%	1.11%
% of Gross Profit		134.82%	567.86%
Operating Expenses	$22.20M	$15.16M	$75.86M
YoY Change	-11.43%	-46.74%	-33.05%
Operating Profit	-$22.20M	-$15.05M	-$75.75M
YoY Change	-11.43%		3.32%
Interest Expense	$293.0K	$4.645M	$521.0K
YoY Change	248.81%	-22219.05%	53.24%
% of Operating Profit
Other Income/Expense, Net	$5.629M	$796.0K	$7.302M
YoY Change	1715.81%	-84.0%	-58.81%
Pretax Income	-$16.57M	-$10.42M	-$68.45M
YoY Change	-33.06%	-55.67%	23.14%
Income Tax	$173.0K	$28.00K	$253.0K
% Of Pretax Income
Net Earnings	-$16.74M	-$10.45M	-$68.70M
YoY Change	-32.59%	-55.07%	23.63%
Net Earnings / Revenue		-2281.88%	-15000.22%
Basic Earnings Per Share	-$0.03		-$0.13
Diluted Earnings Per Share	-$0.03	-$0.02	-$0.13
COMMON SHARES
Basic Shares Outstanding	631.9M shares	605.0M shares	529.1M shares
Diluted Shares Outstanding	621.5M shares		529.1M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$291.4M	$227.8M	$227.8M
YoY Change	119.5%	53.54%	53.54%
Cash & Equivalents	$291.4M	$227.8M	$227.8M
Short-Term Investments
Other Short-Term Assets	$2.073M	$3.388M	$5.887M
YoY Change	-17.9%	64.23%	-3.49%
Inventory
Prepaid Expenses	$1.561M	$2.499M
Receivables
Other Receivables
Total Short-Term Assets	$306.9M	$243.0M	$243.0M
YoY Change	100.64%	42.89%	42.89%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.00K	$73.00K	$927.0K
YoY Change	-83.1%	-8.75%	-5.31%
Goodwill	$545.0K	$545.0K
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$15.00M	$15.00M	$15.00M
YoY Change	0.0%	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$16.26M	$16.47M	$16.47M
YoY Change	-0.64%	-0.31%	-0.31%
TOTAL ASSETS
Total Short-Term Assets	$306.9M	$243.0M	$243.0M
Total Long-Term Assets	$16.26M	$16.47M	$16.47M
Total Assets	$323.1M	$259.5M	$259.5M
YoY Change	90.85%	39.06%	39.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.237M	$2.910M	$2.910M
YoY Change	-10.26%	-71.03%	-71.03%
Accrued Expenses	$17.70M	$13.75M	$14.43M
YoY Change	-38.7%	-38.21%	-37.01%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$26.52M	$19.03M	$19.03M
YoY Change	-30.02%	-43.06%	-43.06%
LONG-TERM LIABILITIES
Long-Term Debt	$19.81M	$9.768M	$9.768M
YoY Change	304.27%	100.41%	100.41%
Other Long-Term Liabilities	$65.00K	$205.0K	$205.0K
YoY Change	-63.28%	-28.32%	-28.32%
Total Long-Term Liabilities	$19.87M	$9.973M	$9.973M
YoY Change	289.3%	93.28%	93.28%
TOTAL LIABILITIES
Total Short-Term Liabilities	$26.52M	$19.03M	$19.03M
Total Long-Term Liabilities	$19.87M	$9.973M	$9.973M
Total Liabilities	$46.40M	$29.00M	$29.00M
YoY Change	7.88%	-24.83%	-24.83%
SHAREHOLDERS EQUITY
Retained Earnings	-$350.1M	-$333.1M
YoY Change	21.27%	26.31%
Common Stock	$41.75M	$40.53M
YoY Change	29.74%	27.22%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$1.208M	$1.549M
YoY Change	63.46%	156.88%
Treasury Stock Shares
Shareholders Equity	$276.7M	$230.5M	$230.5M
YoY Change
Total Liabilities & Shareholders Equity	$323.1M	$259.5M	$259.5M
YoY Change	90.85%	39.06%	39.06%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$16.74M	-$10.45M	-$68.70M
YoY Change	-32.59%	-55.07%	23.63%
Depreciation, Depletion And Amortization	$157.0K	$151.0K	$636.0K
YoY Change	-3.68%	-6.79%	1.11%
Cash From Operating Activities	-$5.782M	-$7.738M	-$59.86M
YoY Change	-60.16%	-55.33%	80.01%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00	$29.00K
YoY Change		-100.0%	141.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	$0.00	-$29.00K
YoY Change		-100.0%	141.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$149.8M
YoY Change			20336.15%
Debt Paid & Issued, Net			$5.000M
YoY Change
Cash From Financing Activities	$68.69M	2.614M	$140.8M
YoY Change	-9560.74%	-390.12%	-2402.08%
NET CHANGE
Cash From Operating Activities	-$5.782M	-7.738M	-$59.86M
Cash From Investing Activities	$0.00	0.000	-$29.00K
Cash From Financing Activities	$68.69M	2.614M	$140.8M
Net Change In Cash	$63.59M	-5.124M	$79.45M
YoY Change	-507.2%	-71.88%	-300.59%
FREE CASH FLOW
Cash From Operating Activities	-$5.782M	-$7.738M	-$59.86M
Capital Expenditures	$0.00	$0.00	$29.00K
Free Cash Flow	-$5.782M	-$7.738M	-$59.89M
YoY Change	-60.16%	-55.33%	80.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001657312
CY2022	dei	Document Type DocumentType	10-K
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-38067
CY2022	dei	Entity Registrant Name EntityRegistrantName	Verona Pharma plc
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	X0
CY2022	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1489389
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	3 More London Riverside
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	London
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	SE1 2RE
CY2022	dei	Entity Address Country EntityAddressCountry	GB
CY2022	dei	Country Region CountryRegion	44
CY2022	dei	City Area Code CityAreaCode	203
CY2022	dei	Local Phone Number LocalPhoneNumber	283 4200
CY2022	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value £0.05 per share*
CY2022	dei	Trading Symbol TradingSymbol	VRNA
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Small Business EntitySmallBusiness	true
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022Q2	dei	Entity Public Float EntityPublicFloat	212100000	usd
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	631904598	shares
CY2022	dei	Auditor Firm AuditorFirmId	876
CY2022	dei	Auditor Firm AuditorFirmId	876
CY2022	dei	Auditor Name AuditorName	PricewaterhouseCoopers LLP
CY2022	dei	Auditor Location AuditorLocation	Reading, United Kingdom
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	227827000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	148380000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2499000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4037000	usd
CY2022Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	9282000	usd
CY2021Q4	vrna	Tax Credit And Income Taxes Receivable Current TaxCreditAndIncomeTaxesReceivableCurrent	15583000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3388000	usd
CY2021Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2063000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	242996000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	170063000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	73000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	80000	usd
CY2022Q4	us-gaap	Goodwill Goodwill	545000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	545000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Noncurrent ContractWithCustomerAssetNetNoncurrent	15000000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	854000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	899000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16472000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	16524000	usd
CY2022Q4	us-gaap	Assets Assets	259468000	usd
CY2021Q4	us-gaap	Assets Assets	186587000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2910000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10044000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13752000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22256000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	675000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	648000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	283000	usd
CY2021Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	147000	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1409000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	327000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	19029000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	33422000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	9768000	usd
CY2021Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	4874000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	205000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	286000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	9973000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5160000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	29002000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	38582000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	631338246	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	489177550	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	606301054	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	480082966	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	40526000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	31855000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	529187000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	385070000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	1549000	usd
CY2021Q4	us-gaap	Treasury Stock Value TreasuryStockValue	603000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4601000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-333097000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-263716000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	259468000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	186587000	usd
CY2022	us-gaap	Revenues Revenues	458000	usd
CY2021	us-gaap	Revenues Revenues	40000000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	346000	usd
CY2021	us-gaap	Investment Income Net InvestmentIncomeNet	14000	usd
CY2022	us-gaap	Interest Expense InterestExpense	521000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2022	us-gaap	Gross Profit GrossProfit	112000	usd
CY2021	us-gaap	Gross Profit GrossProfit	40000000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	49283000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79406000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	26579000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	33907000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	75862000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	113313000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-75750000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-73313000	usd
CY2022	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	9634000	usd
CY2021	vrna	Gain Loss From Research And Development Tax Credit GainLossFromResearchAndDevelopmentTaxCredit	15630000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-815000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Investment Income Net InvestmentIncomeNet	2821000	usd
CY2021	us-gaap	Interest Expense InterestExpense	340000	usd
CY2022	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	0	usd
CY2021	vrna	Unrealized Gain Loss On Warrants UnrealizedGainLossOnWarrants	2246000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3817000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	176000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7302000	usd
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	17726000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-68448000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55587000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	253000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55569000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	184854000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55569000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	25425000	usd
CY2021	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	6850000	usd
CY2021	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	588000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	148005000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2022	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	0	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1372000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	14121000	usd
CY2022	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	4723000	usd
CY2022	vrna	Adjustments To Additional Paid In Capital Reclassification From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalReclassificationFromShareBasedCompensation	-128000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	230466000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55569000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3817000	usd
CY2021	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	176000	usd
CY2022	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	80000	usd
CY2021	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	114000	usd
CY2022	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	108000	usd
CY2021	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	125000	usd
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-815000	usd
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	usd
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-2246000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	14121000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	25425000	usd
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	636000	usd
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	629000	usd
CY2022	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	0	usd
CY2021	vrna	Increase Decrease In Equity Interest Receivable IncreaseDecreaseInEquityInterestReceivable	15000000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-1538000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-501000	usd
CY2022	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	-3964000	usd
CY2021	vrna	Increase Decrease In Tax And Tax Credit Receivables Current IncreaseDecreaseInTaxAndTaxCreditReceivablesCurrent	6924000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1325000	usd
CY2021	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	343000	usd
CY2022	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	440000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-7146000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	9866000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-8504000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	11389000	usd
CY2022	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-597000	usd
CY2021	vrna	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-373000	usd
CY2022	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	136000	usd
CY2021	us-gaap	Increase Decrease In Accrued Taxes Payable IncreaseDecreaseInAccruedTaxesPayable	147000	usd
CY2022	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	1196000	usd
CY2021	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-379000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59862000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-33254000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	29000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	12000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-29000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-12000	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	149797000	usd
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	733000	usd
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	9533000	usd
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	10000000	usd
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	usd
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	245000	usd
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	5000000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0	usd
CY2022	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	850000	usd
CY2021	us-gaap	Payments Of Loan Costs PaymentsOfLoanCosts	0	usd
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4723000	usd
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	6850000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1372000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	140818000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-6117000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1480000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-223000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	79447000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-39606000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148380000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187986000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	227827000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	148380000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	120000	usd
CY2021	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	348000	usd
CY2021	us-gaap	Interest Paid Net InterestPaidNet	215000	usd
CY2022	vrna	Number Of Wholly Owned Subsidiaries NumberOfWhollyOwnedSubsidiaries	1	subsidiary
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-333100000	usd
CY2022Q3	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8
CY2022Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.05
CY2021	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	873104	shares
CY2021Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.86
CY2021	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	700000	usd
CY2022	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	80696	shares
CY2022Q4	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	0.86
CY2022	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	100000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Use of estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual and prepayment of research and development expenses and the fair value of share-based compensation. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from the Company’s estimates.</span></div>
CY2022	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2022	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:110%">Concentration of credit risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">Financial instruments that potentially subject the Company to concentration of credit risk consist of principally cash and cash equivalents, bank deposits and certain receivables. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company holds cash and cash equivalents with highly rated financial institutions and in highly rated money market funds and the Company has not experienced any significant credit losses in these accounts and does not believe the Company is exposed to any significant credit risk on these instruments.</span></div>
CY2022Q4	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	38000	usd
CY2021Q4	vrna	Prepaid Research And Development Fees Current PrepaidResearchAndDevelopmentFeesCurrent	2169000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	2027000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	1555000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	434000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	313000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2499000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4037000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.04
CY2021Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.08
CY2022Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P1Y6M
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P1Y9M18D
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	675000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	215000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	17000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	907000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	27000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	880000	usd
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	600000	usd
CY2022Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	12314000	usd
CY2021Q4	vrna	Accrued Research And Development Fees Current AccruedResearchAndDevelopmentFeesCurrent	21336000	usd
CY2022Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	1364000	usd
CY2021Q4	vrna	Accrued Professional Fees Listing And General Corporate Costs Current AccruedProfessionalFeesListingAndGeneralCorporateCostsCurrent	919000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	74000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13752000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	22256000	usd
CY2022	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2021	vrna	Class Of Warrant Or Right Number Of Exercised Or Forfeited ClassOfWarrantOrRightNumberOfExercisedOrForfeited	0	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	31115926	shares
CY2016Q4	vrna	Class Of Warrant Or Right Issue Price Of Warrants Or Rights ClassOfWarrantOrRightIssuePriceOfWarrantsOrRights	1.4365
CY2016Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	0.4	shares
CY2016Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	31003155	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	12401262	shares
CY2021Q4	vrna	Class Of Warrant Or Right Intrinsic Value ClassOfWarrantOrRightIntrinsicValue	0	usd
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.7238
CY2021Q4	us-gaap	Warrants And Rights Outstanding Term WarrantsAndRightsOutstandingTerm	P0Y3M29D
CY2021Q4	vrna	Warrant Liability Current WarrantLiabilityCurrent	0	usd
CY2020Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	2246000	usd
CY2021	vrna	Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Fair Value Adjustment FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityFairValueAdjustment	-2246000	usd
CY2021Q4	us-gaap	Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue	0	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	14121000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25425000	usd
CY2022Q4	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8	rate
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	13125672	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.41
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M18D
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1696000	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.72
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2126472	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.06
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	12695200	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.38
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	950000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	9024000	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.90
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	620016	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.04
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1822688	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.75
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19276496	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	1.22
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y2M12D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	39412000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	10382256	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.48
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y4M24D
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	18543000	usd
CY2022Q4	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8	rate
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	2413000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1372000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0	usd
CY2022	vrna	Share Based Compensation Arrangement By Share Based Payment Award Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue	19600000	usd
CY2021	vrna	Share Based Compensation Arrangement By Share Based Payment Award Grants In Period Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriodGrantDateFairValue	3100000	usd
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.98
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.73
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.04
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.97
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	0.97
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.07
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.03
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	0.96
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.01
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	20500000	usd
CY2022	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P1Y
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	319000	usd
CY2021	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	274000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3868000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	4850000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-72316000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-60437000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-68448000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55587000	usd
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	253000	usd
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	-18000	usd
CY2022	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Current Federal State And Local Tax Expense Benefit CurrentFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	253000	usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-18000	usd
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Federal State And Local Tax Expense Benefit DeferredFederalStateAndLocalTaxExpenseBenefit	0	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	253000	usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-18000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.190
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.190
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.018
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.075
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.080
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.109
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.021
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.026
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.116
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.030
CY2022	vrna	Effective Income Tax Rate Reconciliation Capital Allowances Percent EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent	-0.001
CY2021	vrna	Effective Income Tax Rate Reconciliation Capital Allowances Percent EffectiveIncomeTaxRateReconciliationCapitalAllowancesPercent	-0.001
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.004
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2022Q4	vrna	Deferred Tax Liabilities Contingent Liability DeferredTaxLiabilitiesContingentLiability	34565000	usd
CY2021Q4	vrna	Deferred Tax Liabilities Contingent Liability DeferredTaxLiabilitiesContingentLiability	8903000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	34565000	usd
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8903000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	38893000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	26931000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	32700000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	7992000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	11964000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	4228000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	-516000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	83041000	usd
CY2022Q4	dei	Entity Listing Depository Receipt Ratio EntityListingDepositoryReceiptRatio	8	rate
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	39155000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	48476000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	30252000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	0	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	155600000	usd
CY2021Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	104300000	usd
CY2022Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	usd
CY2022	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2021Q4	us-gaap	Income Tax Examination Penalties Accrued IncomeTaxExaminationPenaltiesAccrued	0	usd
CY2021Q4	us-gaap	Income Tax Examination Interest Accrued IncomeTaxExaminationInterestAccrued	0	usd
CY2021	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
CY2022Q4	us-gaap	Income Tax Examination Interest Accrued IncomeTaxExaminationInterestAccrued	0	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-68701000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-55569000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-68701000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-68701000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-55569000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-55569000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	529071526	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	529071526	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	473188457	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	473188457	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.13
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	53818840	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	63443814	shares
CY2022Q4	us-gaap	Loss Contingency Estimate Of Possible Loss LossContingencyEstimateOfPossibleLoss	1500000	usd
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0	usd

Files In Submission

Name	View Source	Status
0001657312-23-000006-index-headers.html	Edgar Link	pending
0001657312-23-000006-index.html	Edgar Link	pending
0001657312-23-000006.txt	Edgar Link	pending
0001657312-23-000006-xbrl.zip	Edgar Link	pending
consentletter-fy22.htm	Edgar Link	pending
exhibit211q422.htm	Edgar Link	pending
exhibit311q422.htm	Edgar Link	pending
exhibit312q422.htm	Edgar Link	pending
exhibit321q422.htm	Edgar Link	pending
exhibit322q422.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrna-20221231.htm	Edgar Link	pending
vrna-20221231.xsd	Edgar Link	pending
vrna-20221231_g1.jpg	Edgar Link	pending
vrna-20221231_g10.jpg	Edgar Link	pending
vrna-20221231_g11.jpg	Edgar Link	pending
vrna-20221231_g12.jpg	Edgar Link	pending
vrna-20221231_g13.jpg	Edgar Link	pending
vrna-20221231_g14.jpg	Edgar Link	pending
vrna-20221231_g2.jpg	Edgar Link	pending
vrna-20221231_g3.jpg	Edgar Link	pending
vrna-20221231_g4.jpg	Edgar Link	pending
vrna-20221231_g5.jpg	Edgar Link	pending
vrna-20221231_g6.jpg	Edgar Link	pending
vrna-20221231_g7.jpg	Edgar Link	pending
vrna-20221231_g8.jpg	Edgar Link	pending
vrna-20221231_g9.jpg	Edgar Link	pending
vrna-20221231_def.xml	Edgar Link	unprocessable
vrna-20221231_pre.xml	Edgar Link	unprocessable
vrna-20221231_htm.xml	Edgar Link	completed
vrna-20221231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
vrna-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRNA
Verona Pharma PLC Stock $vrna

2023 Q1 Form 10-K Financial Statement

#000165731223000006 Filed on March 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA Verona Pharma PLC Stock $vrna

2023 Q1 Form 10-K Financial Statement

#000165731223000006 Filed on March 07, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRNA
Verona Pharma PLC Stock $vrna